Cargando…

P1638: EARLY USE OF ELTROMBOPAG IN ADULT PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE CORTICOSTEROID THERAPY – AN AD HOC ANALYSIS OF THE TAPER TRIAL RESULTS

Detalles Bibliográficos
Autores principales:	Ghanima, W., Zaja, F., Maier, J., Haenig, J., Lee, J., Cooper, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429140/ http://dx.doi.org/10.1097/01.HS9.0000849408.24775.41

Ejemplares similares

Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States
por: Cuker, Adam, et al.
Publicado: (2023)

Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients
por: Dionisi, Marco, et al.
Publicado: (2021)

P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
por: Cooper, Nichola, et al.
Publicado: (2023)

PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
por: Zaja, Francesco, et al.
Publicado: (2023)

Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life
por: Cooper, Nichola, et al.
Publicado: (2020)

Relapse of SARS upon tapering corticosteroid
por: Chien, Jung-Yien, et al.
Publicado: (2004)

PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
por: Cooper, Nichola, et al.
Publicado: (2023)

The Impact of Ethnicity on the Response to Eltrombopag in Patients With Immune Thrombocytopenia (ITP) in Qatar: A Single Institution Experience
por: Yassin, Mohamed A, et al.
Publicado: (2022)

P1639: UTILITY OF NEXT GENERATION SEQUENCING TECHNIQUES TO EVALUATE POSSIBLE CAUSES OF REFRACTORINESS TO TREATMENT WITH ELTROMBOPAG IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN SPAIN.
por: Gonzalez-Lopez, T. J., et al.
Publicado: (2022)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

Eltrombopag and its beneficial role in management of ulcerative Colitis associated with ITP as an upfront therapy case report
por: Abdelmahmuod, Elabbass A., et al.
Publicado: (2021)

PB2311: LOW-DOSE PREDNISON AND ELTROMBOPAG COMBINATION AS FRONTLINE TREATMENT IN NEWLY DIAGNOSED ITP PATIENTS
por: Liu, S.-Y., et al.
Publicado: (2022)

P1614: TAPERING SCHEME AND SUSTAINED RESPONSE IN PATIENTS WITH ITP TREATED WITH FOSTAMATINIB
por: Mingot-Castellano, María Eva, et al.
Publicado: (2023)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management
por: Terrell, Deirdra R., et al.
Publicado: (2020)

Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment
por: Cooper, Nichola, et al.
Publicado: (2020)

Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial
por: Ji, Jiang, et al.
Publicado: (2023)

Adding eltrombopag to immunosuppression: the importance of predicting outcome
por: Tichelli, André, et al.
Publicado: (2022)

Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post‐hoc analysis of the EXTEND study
por: Meyer, Oliver, et al.
Publicado: (2021)

How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh)
por: Chakrabarti, Prantar, et al.
Publicado: (2022)

Refractory chronic “ITP”: When platelet size matters
por: Baliakas, Panagiotis, et al.
Publicado: (2018)

1638. Measles Outbreak Risk Assessment for Transplant Candidates and Recipients
por: Kreiger-Benson, Elana, et al.
Publicado: (2019)

Efficacy and Safety Analysis of Combination Therapy Consisting of Intravenous Immunoglobulin and Corticosteroids versus Respective Monotherapies in the Treatment of Relapsed ITP in Adults
por: Fang, Lijun, et al.
Publicado: (2023)

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
por: Tsykunova, Galina, et al.
Publicado: (2022)

An ITP workbook
por: Kalman, J A
Publicado: (1986)

Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol
por: Shimano, Kristin A, et al.
Publicado: (2021)

Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China
por: Zhang, Zhuxin, et al.
Publicado: (2023)

Oral Corticosteroids Tapering in Severe Asthma
por: Boulet, Louis-Philippe, et al.
Publicado: (2021)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia
por: Maraziti, Giorgio, et al.
Publicado: (2021)

Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome
por: Xu, Liping, et al.
Publicado: (2022)

1820. Efficacy of Pulse-Taper Corticosteroid Adjunctive Therapy for Refractory Non-HIV Cryptococcal Meningoencephalitis
por: Anjum, Seher, et al.
Publicado: (2019)

1638P Experience with telemedicine during COVID-19 pandemic
por: Soriano, S., et al.
Publicado: (2021)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
por: Chang, H., et al.
Publicado: (2022)

Eltrombopag use for refractory immune thrombocytopenia in pregnancy: A case report
por: Weingarten, Sarah J., et al.
Publicado: (2020)

Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering Scheme
por: González-López, Tomás José, et al.
Publicado: (2023)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
por: Zhang, Zhuxin, et al.
Publicado: (2023)

Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism
por: Nedumannil, Rithin, et al.
Publicado: (2022)

Cerebral venous thrombosis in refractory idiopathic thrombocytopenia treated with eltrombopag
por: Nambiar, Vivek, et al.
Publicado: (2016)

Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease
por: Wang, Juan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bgev8vskoi05ks9kmq6dpb5u9l